Correlation Between Opthea and Coya Therapeutics,
Can any of the company-specific risk be diversified away by investing in both Opthea and Coya Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Opthea and Coya Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Opthea and Coya Therapeutics, Common, you can compare the effects of market volatilities on Opthea and Coya Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Opthea with a short position of Coya Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Opthea and Coya Therapeutics,.
Diversification Opportunities for Opthea and Coya Therapeutics,
0.66 | Correlation Coefficient |
Poor diversification
The 3 months correlation between Opthea and Coya is 0.66. Overlapping area represents the amount of risk that can be diversified away by holding Opthea and Coya Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Coya Therapeutics, Common and Opthea is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Opthea are associated (or correlated) with Coya Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Coya Therapeutics, Common has no effect on the direction of Opthea i.e., Opthea and Coya Therapeutics, go up and down completely randomly.
Pair Corralation between Opthea and Coya Therapeutics,
Considering the 90-day investment horizon Opthea is expected to under-perform the Coya Therapeutics,. But the stock apears to be less risky and, when comparing its historical volatility, Opthea is 1.51 times less risky than Coya Therapeutics,. The stock trades about -0.09 of its potential returns per unit of risk. The Coya Therapeutics, Common is currently generating about 0.03 of returns per unit of risk over similar time horizon. If you would invest 645.00 in Coya Therapeutics, Common on August 29, 2024 and sell it today you would lose (7.00) from holding Coya Therapeutics, Common or give up 1.09% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Significant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Opthea vs. Coya Therapeutics, Common
Performance |
| Timeline |
| Opthea |
| Coya Therapeutics, Common |
Opthea and Coya Therapeutics, Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Opthea and Coya Therapeutics,
The main advantage of trading using opposite Opthea and Coya Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Opthea position performs unexpectedly, Coya Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Coya Therapeutics, will offset losses from the drop in Coya Therapeutics,'s long position.The idea behind Opthea and Coya Therapeutics, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.| Coya Therapeutics, vs. Cue Biopharma | Coya Therapeutics, vs. Lantern Pharma | Coya Therapeutics, vs. Fennec Pharmaceuticals | Coya Therapeutics, vs. Eliem Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Complementary Tools
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |